{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    42,
    43,
    44,
    49,
    53,
    60,
    63,
    64,
    65,
    66,
    67,
    68,
    70,
    78,
    89
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "first dose of \nstudy drug"
      },
      {
        "id": "anchor_2",
        "definition": "Date of subject randomization",
        "anchorType": "Randomization",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "randomization visit"
      },
      {
        "id": "anchor_3",
        "definition": "Baseline visit/assessment",
        "anchorType": "Baseline",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Baseline assessment"
      },
      {
        "id": "anchor_4",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Informed \nconsent"
      },
      {
        "id": "anchor_5",
        "definition": "procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "procedure"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "once daily"
      },
      {
        "id": "rep_daily_2",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "bid"
      },
      {
        "id": "rep_interval_2",
        "type": "Interval",
        "sourceText": "tid"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "startOffset": "P8D",
        "endOffset": "P16D",
        "sourceText": "Week 8 to Week 16"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "endOffset": "P3D",
        "sourceText": "Weeks\n0 to 3"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "startOffset": "P4D",
        "endOffset": "P7D",
        "sourceText": "Weeks\n4 to 7"
      },
      {
        "id": "rep_window_4",
        "type": "Continuous",
        "startOffset": "P8D",
        "endOffset": "P11D",
        "sourceText": "Weeks\n8 to 11"
      },
      {
        "id": "rep_window_5",
        "type": "Continuous",
        "startOffset": "P12D",
        "endOffset": "P15D",
        "sourceText": "Weeks\n12 to 15"
      },
      {
        "id": "rep_window_6",
        "type": "Continuous",
        "startOffset": "P16D",
        "endOffset": "P19D",
        "sourceText": "Weeks\n16 to 19"
      },
      {
        "id": "rep_window_7",
        "type": "Continuous",
        "startOffset": "P20D",
        "endOffset": "P104D",
        "sourceText": "Weeks\n20 to 104"
      },
      {
        "id": "rep_window_8",
        "type": "Continuous",
        "startOffset": "P8D",
        "endOffset": "P16D",
        "sourceText": "from Week 8 to Week 16"
      },
      {
        "id": "rep_window_9",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_10",
        "type": "Continuous",
        "sourceText": "Treatment Period"
      },
      {
        "id": "rep_window_16",
        "type": "Continuous",
        "sourceText": "follow-up period"
      },
      {
        "id": "rep_window_18",
        "type": "Continuous",
        "sourceText": "2 \nhours after"
      },
      {
        "id": "rep_llm_1",
        "type": "Daily",
        "startOffset": "null",
        "endOffset": "null",
        "interval": "P1D",
        "exitCondition": "null",
        "sourceText": "Ability to Perform Physical Activities of Daily Living (APPADL)"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "LEAD_IN",
          "TREATMENT",
          "SAFETY_FOLLOW_UP",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "End of Study",
          "Primary Endpoint Visit",
          "Randomization",
          "Safety Follow-up Visit"
        ],
        "sourceText": "[{'condition': 'Permanent Discontinuation from Study Treatment', 'path': ['EARLY_TREATMENT_DISCONTINUATION_VISIT', 'CONTINUED_STUDY_OBSERVATION', 'SAFETY_FOLLOW_UP']}, {'condition': 'Temporary Interruption of Study Treatment', 'path': ['TREATMENT_PAUSE', 'TREATMENT_RE_INITIATION']}, {'condition': 'Inadvertently Enrolled Patients', 'path': ['IMMEDIATE_DISCONTINUATION']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Single",
        "rationale": "EPISODE signals: 1; SINGLE signals: 2"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Single",
        "rationale": "SINGLE signals: 5"
      },
      {
        "activityId": "Concomitant \nMedications",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Laboratory Tests",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 2"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Drug Administration",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 2"
      },
      {
        "activityId": "Imaging",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Epro",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Informed Consent",
        "executionType": "Single",
        "rationale": "Obtained once at the start of the screening process."
      },
      {
        "activityId": "LY3298176 Administration",
        "executionType": "Single",
        "rationale": "Administered once weekly throughout the treatment period."
      },
      {
        "activityId": "Insulin Glargine Titration",
        "executionType": "Single",
        "rationale": "Dose adjustments are based on specific glucose targets and conditional algorithms."
      },
      {
        "activityId": "Efficacy and Safety Assessments",
        "executionType": "Single",
        "rationale": "Scheduled assessments occurring at multiple study visits as per the Schedule of Activities."
      },
      {
        "activityId": "Continuous Glucose Monitoring (CGM)",
        "executionType": "Single",
        "rationale": "Involves continuous data collection over a specific multi-day period to assess glycemic profiles."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "timing_before",
        "text": "a Baseline assessments must be completed before processing in the interactive web-response system (IWRS).",
        "footnoteId": "fn_1",
        "structuredCondition": "sequence.before(baseline_assessments, IWRS_processing)",
        "appliesToActivityIds": [
          "Baseline assessments"
        ],
        "sourceText": "a Baseline assessments must be completed before processing in the interactive web-response system (I"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "general",
        "text": "b Patients who are unable or unwilling to continue in the study for any reason will perform an ET visit.",
        "footnoteId": "fn_2",
        "structuredCondition": "if(patient_status == 'discontinued' || patient_status == 'unwilling_to_continue')",
        "appliesToActivityIds": [
          "ET visit"
        ],
        "sourceText": "b Patients who are unable or unwilling to continue in the study for any reason will perform an ET vi"
      },
      {
        "id": "fn_cond_3",
        "conditionType": "general",
        "text": "c The visit date is determined in relation to the date of the randomization visit (± the allowed visit window).",
        "footnoteId": "fn_3",
        "structuredCondition": "visit_date = randomization_date + visit_window",
        "appliesToActivityIds": [
          "All visits"
        ],
        "sourceText": "c The visit date is determined in relation to the date of the randomization visit (± the allowed vis"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "procedure_timepoints",
        "text": "d On visits 3, 5, 7, 11, 13, 15, 16, 18, 23, 24, 27, 29, ET, and at follow-up (801), patients should be reminded to report to the site in a fasting condition.",
        "footnoteId": "fn_4",
        "structuredCondition": "patient_state == 'fasting'",
        "appliesToActivityIds": [
          "Visit 3",
          "Visit 5",
          "Visit 7",
          "Visit 11",
          "Visit 13",
          "Visit 15",
          "Visit 16",
          "Visit 18",
          "Visit 23",
          "Visit 24",
          "Visit 27",
          "Visit 29",
          "ET",
          "Follow-up (801)"
        ],
        "sourceText": "d On visits 3, 5, 7, 11, 13, 15, 16, 18, 23, 24, 27, 29, ET, and at follow-up (801), patients should"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "general",
        "text": "v In the event of systemic drug hypersensitivity reactions, additional blood samples will be collected including ADA, PK, and exploratory biomarker sample.",
        "footnoteId": "fn_5",
        "structuredCondition": "if(event == 'systemic_drug_hypersensitivity_reaction')",
        "appliesToActivityIds": [
          "ADA blood sample",
          "PK blood sample",
          "Exploratory biomarker sample"
        ],
        "sourceText": "v In the event of systemic drug hypersensitivity reactions, additional blood samples will be collect"
      },
      {
        "id": "fn_cond_6",
        "conditionType": "timing_before",
        "text": "y PROs should be completed before any other study procedures if the patient is not adversely affected by the fasting condition.",
        "footnoteId": "fn_6",
        "structuredCondition": "if(patient_state != 'adversely_affected_by_fasting') { sequence.before(PRO, all_other_procedures) }",
        "appliesToActivityIds": [
          "PROs"
        ],
        "sourceText": "y PROs should be completed before any other study procedures if the patient is not adversely affecte"
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "z When the sponsor determines that the study has met the completion criteria, all patients remaining in the study will return to the site for a FTV.",
        "footnoteId": "fn_7",
        "structuredCondition": "if(sponsor_status == 'study_completion_criteria_met')",
        "appliesToActivityIds": [
          "FTV"
        ],
        "sourceText": "z When the sponsor determines that the study has met the completion criteria, all patients remaining"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Mean change in HbA1c",
        "endpointType": "Primary",
        "inputs": [
          "HbA1c_baseline",
          "HbA1c_week52"
        ],
        "timeWindow": {
          "reference": "baseline",
          "duration": "P52W"
        },
        "algorithm": "HbA1c_week52 - HbA1c_baseline",
        "successCriteria": "Noninferiority of LY3298176 10 mg and/or 15 mg to insulin glargine (2-sided 0.05 level)",
        "sourceText": "The primary endpoint will be the mean change in hemoglobin A1c (HbA1c) levels from baseline to 52 weeks."
      },
      {
        "id": "ep_2",
        "name": "Key Secondary: Mean change in HbA1c (5 mg)",
        "endpointType": "Secondary",
        "inputs": [
          "HbA1c_baseline",
          "HbA1c_week52"
        ],
        "timeWindow": {
          "reference": "baseline",
          "duration": "P52W"
        },
        "algorithm": "HbA1c_week52 - HbA1c_baseline",
        "successCriteria": "Noninferiority of LY3298176 5 mg to insulin glargine",
        "sourceText": "To demonstrate that QW LY3298176 5 mg is noninferior to insulin glargine for change from baseline in HbA1c at 52 weeks"
      },
      {
        "id": "ep_3",
        "name": "Key Secondary: Mean change in body weight",
        "endpointType": "Secondary",
        "inputs": [
          "weight_baseline",
          "weight_week52"
        ],
        "timeWindow": {
          "reference": "baseline",
          "duration": "P52W"
        },
        "algorithm": "weight_week52 - weight_baseline",
        "successCriteria": "Superiority of LY3298176 (5 mg, 10 mg, and/or 15 mg) to insulin glargine",
        "sourceText": "To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine for change from baseline in weight at 52 weeks"
      },
      {
        "id": "ep_4",
        "name": "Key Secondary: Superiority in HbA1c",
        "endpointType": "Secondary",
        "inputs": [
          "HbA1c_baseline",
          "HbA1c_week52"
        ],
        "timeWindow": {
          "reference": "baseline",
          "duration": "P52W"
        },
        "algorithm": "HbA1c_week52 - HbA1c_baseline",
        "successCriteria": "Superiority of LY3298176 (5 mg, 10 mg, and/or 15 mg) to insulin glargine",
        "sourceText": "To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine for change from baseline in HbA1c at 52 weeks"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Change from baseline in HbA1c",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "HbA1c"
        ],
        "derivationRule": "HbA1c_at_52_weeks - HbA1c_at_baseline",
        "baselineDefinition": "Value at randomization/baseline",
        "baselineVisit": "Baseline",
        "analysisWindow": "52 weeks",
        "imputationRule": "Modified intention-to-treat (mITT) population analysis",
        "unit": "%"
      },
      {
        "id": "dv_2",
        "name": "Change from baseline in body weight",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "Body weight"
        ],
        "derivationRule": "weight_at_52_weeks - weight_at_baseline",
        "baselineDefinition": "Value at randomization/baseline",
        "baselineVisit": "Baseline",
        "analysisWindow": "52 weeks",
        "imputationRule": "Modified intention-to-treat (mITT) population analysis",
        "unit": "kg"
      },
      {
        "id": "dv_3",
        "name": "Proportion of patients with HbA1c <7.0%",
        "variableType": "Categorical",
        "sourceVariables": [
          "HbA1c"
        ],
        "derivationRule": "If HbA1c < 7.0% then 1 else 0",
        "baselineDefinition": "Not applicable",
        "analysisWindow": "52 weeks",
        "imputationRule": "Modified intention-to-treat (mITT) population analysis",
        "unit": "proportion"
      },
      {
        "id": "dv_4",
        "name": "Change from baseline in fasting serum glucose",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "Fasting serum glucose"
        ],
        "derivationRule": "FSG_at_52_weeks - FSG_at_baseline",
        "baselineDefinition": "Value at randomization/baseline",
        "baselineVisit": "Baseline",
        "analysisWindow": "52 weeks",
        "imputationRule": "Modified intention-to-treat (mITT) population analysis",
        "unit": "mg/dL or mmol/L"
      },
      {
        "id": "dv_5",
        "name": "Proportion of patients achieving weight loss of >=5%, >10%, and >15%",
        "variableType": "Categorical",
        "sourceVariables": [
          "Body weight"
        ],
        "derivationRule": "((weight_at_52_weeks - weight_at_baseline) / weight_at_baseline) * 100",
        "baselineDefinition": "Value at randomization/baseline",
        "baselineVisit": "Baseline",
        "analysisWindow": "52 weeks",
        "imputationRule": "Modified intention-to-treat (mITT) population analysis",
        "unit": "proportion"
      },
      {
        "id": "dv_6",
        "name": "Time to initiation of rescue therapy",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Rescue therapy start date",
          "Randomization date"
        ],
        "derivationRule": "rescue_therapy_date - randomization_date",
        "baselineDefinition": "Date of randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "Up to 52 weeks or end of study",
        "imputationRule": "Censored at last follow-up if no rescue therapy",
        "unit": "days"
      },
      {
        "id": "dv_7",
        "name": "Composite CV endpoint",
        "variableType": "Composite",
        "sourceVariables": [
          "Cardiovascular death",
          "Myocardial infarction",
          "Stroke",
          "Hospitalization for unstable angina"
        ],
        "derivationRule": "Occurrence of any of the four component events",
        "baselineDefinition": "Post-randomization occurrence",
        "analysisWindow": "Study duration",
        "imputationRule": "Adjudicated events",
        "unit": "count/proportion"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Lead In",
        "Treatment",
        "Safety Follow Up",
        "End Of Study",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Lead In",
          "trigger": "Progress to Lead In"
        },
        {
          "fromState": "Lead In",
          "toState": "Treatment",
          "trigger": "Progress to Treatment"
        },
        {
          "fromState": "Treatment",
          "toState": "Safety Follow Up",
          "trigger": "Progress to Safety Follow Up"
        },
        {
          "fromState": "Safety Follow Up",
          "toState": "End Of Study",
          "trigger": "Progress to End Of Study"
        },
        {
          "fromState": "Treatment",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Lead In": "LEAD_IN",
        "Treatment": "TREATMENT",
        "Safety Follow Up": "SAFETY_FOLLOW_UP",
        "End Of Study": "END_OF_STUDY",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "QW LY3298176",
        "frequency": "QW",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 10.0,
            "unit": "mg"
          },
          {
            "amount": 15.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "52 weeks",
        "sourceText": "ascular (CV) risk. The primary endpoint will be the mean change in hemoglobin A1c (HbA1c) levels from baseline to 52 weeks. Objective(s)/Endpoints: Objectives Endpoints Primary  To demonstrate that Q"
      },
      {
        "id": "dosing_2",
        "treatmentName": "with LY3298176",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 5.0,
            "unit": "mg"
          },
          {
            "amount": 10.0,
            "unit": "mg"
          },
          {
            "amount": 15.0,
            "unit": "mg"
          }
        ],
        "sourceText": "uate the relationship between LY3298176 exposure and safety, tolerability, and efficacy measures  Population PK and PD parameters Tertiary/Exploratory  To characterize long-term glycemic control wit"
      },
      {
        "id": "dosing_3",
        "treatmentName": "compare LY3298176",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 5.0,
            "unit": "mg"
          },
          {
            "amount": 10.0,
            "unit": "mg"
          },
          {
            "amount": 15.0,
            "unit": "mg"
          }
        ],
        "sourceText": "posure and safety, tolerability, and efficacy measures  Population PK and PD parameters Tertiary/Exploratory  To characterize long-term glycemic control with LY3298176 5 mg, 10 mg, and 15 mg  To co"
      },
      {
        "id": "dosing_llm_1",
        "treatmentName": "LY3298176",
        "frequency": "QW",
        "route": "SC",
        "startDay": 1,
        "durationDescription": "Not specified in provided text",
        "titrationSchedule": "Mentioned in Section 7.4.1 'Study Drugs' and 7.2.1.1, though specific increments are not in this excerpt.",
        "doseModifications": [
          "Dosage modification details located in Section 7.4"
        ]
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Insulin Glargine",
        "frequency": "QD",
        "route": "SC",
        "startDay": 1,
        "durationDescription": "Not specified in provided text",
        "titrationSchedule": "Mentioned in Section 7.2.1.2 and 7.4.1.",
        "doseModifications": [
          "Reduction and/or Discontinuation of Concomitant Antihyperglycemic Medications (Section 7.4.2)"
        ]
      }
    ],
    "visitWindows": [
      {
        "id": "visit_6",
        "visitName": "Screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Study Period I: Screening",
        "sourceText": "Screening Lead in Treatment Period"
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "HbA1c target values of <7.0% (53 mmol/mol) at 52 weeks "
      },
      {
        "id": "visit_2",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "(central laboratory) from baseline  The proportion of patients achieving an HbA1c"
      },
      {
        "id": "visit_7",
        "visitName": "Visit 801",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "Visit 801 (safety follow-up visit) should be performed 4 weeks after the ET visit as the final study visit. c The visit date is determined in relation to the date of the randomization visit (± the all"
      },
      {
        "id": "visit_8",
        "visitName": "Visit 2",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "Dilated fundoscopic exam will be performed by an eye care professional (ophthalmologist or optometrist) for all patients between Visit 2 and Visit 3 to exclude patients with proliferative retinopathy "
      },
      {
        "id": "visit_11",
        "visitName": "Visit 1",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "A serum pregnancy test will be performed at Visit 1 for women of childbearing potential only. q A urine pregnancy test must be performed at Visit 3 with the result available prior to randomization and"
      },
      {
        "id": "visit_12",
        "visitName": "Visit 3",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 7,
        "sourceText": "A urine pregnancy test must be performed at Visit 3 with the result available prior to randomization and first injection of study drug(s) for women of childbearing potential only. Additional pregnancy"
      },
      {
        "id": "visit_14",
        "visitName": "Visit 25",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 8,
        "sourceText": "Long-term safety period (Visit 25 to Visit 29): Some patients will continue to receive LY3298176 or insulin glargine for up to, but not longer than, 24 months, as determined by the sponsor."
      },
      {
        "id": "visit_15",
        "visitName": "Visit 29",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 9,
        "sourceText": "attend Visit 29 (24 months) or the FTV are considered to have completed the treatment period. Study Period IV (safety follow-up period) Safety follow-up (Visit 801) visits:"
      },
      {
        "id": "visit_16",
        "visitName": "End of Study",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 10,
        "sourceText": "End of Study Definition End of the study is the date of the last visit or last scheduled procedure shown in the Schedule of Activities (Section 2) for the last patient."
      },
      {
        "id": "visit_17",
        "visitName": "Visit 13",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": false,
        "visitNumber": 11,
        "sourceText": "scheduled visits, the IWRS will have unscheduled visits (for example, Visit 13a) dedicated to provide dispensing information for patients whose dose has been de-escalated. Those patients who have thei"
      },
      {
        "id": "visit_4",
        "visitName": "randomization",
        "targetDay": 1,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 12,
        "epoch": "Study Period II: Treatment Period",
        "sourceText": "or insulin glargine. The randomization will be stratified by country, baseline HbA1c concentration (≤8.5%, ˃8.5% [≤69, ˃69 mmol/mol]), and sodium-glucose co-transporter-2 inhibitors (SGLT-2i) use (Yes"
      },
      {
        "id": "visit_llm_4",
        "visitName": "Week 1",
        "targetDay": 8,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 4,
        "targetWeek": 1,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_llm_5",
        "visitName": "Week 2",
        "targetDay": 15,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 5,
        "targetWeek": 2,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_llm_6",
        "visitName": "Week 3",
        "targetDay": 22,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 6,
        "targetWeek": 3,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_llm_7",
        "visitName": "Week 4",
        "targetDay": 29,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 7,
        "targetWeek": 4,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_llm_8",
        "visitName": "Week 5",
        "targetDay": 36,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 8,
        "targetWeek": 5,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_llm_9",
        "visitName": "Week 6",
        "targetDay": 43,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 9,
        "targetWeek": 6,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_9",
        "visitName": "Week 8",
        "targetDay": 50,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 19,
        "targetWeek": 8,
        "epoch": "Study Period II: Treatment Period",
        "sourceText": "Week 8, the dose adjustment will be determined by the patient in a weekly manner and will be reviewed by the investigator at each office visit. Patient will have weekly visits (clinic or phone) in the"
      },
      {
        "id": "visit_llm_12",
        "visitName": "Week 10",
        "targetDay": 71,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 12,
        "targetWeek": 10,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_llm_13",
        "visitName": "Week 12",
        "targetDay": 85,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 13,
        "targetWeek": 12,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_10",
        "visitName": "Week 16",
        "targetDay": 106,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 22,
        "targetWeek": 16,
        "epoch": "Study Period II: Treatment Period",
        "sourceText": "have weekly visits (clinic or phone) in the first 8 weeks and then visits every 2-3 weeks (clinic or phone) until Week 16 in order to improve compliance with the TTT algorithm. o"
      },
      {
        "id": "visit_llm_16",
        "visitName": "Week 20",
        "targetDay": 141,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 16,
        "targetWeek": 20,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_18",
        "visitName": "Week 24",
        "targetDay": 162,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 24,
        "targetWeek": 24,
        "epoch": "Study Period II: Treatment Period",
        "sourceText": "(Week 24), dose decreases will not be permitted. 7.8. Treatment after the End of the Study"
      },
      {
        "id": "visit_llm_19",
        "visitName": "Week 28",
        "targetDay": 197,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 19,
        "targetWeek": 28,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_llm_20",
        "visitName": "Week 32",
        "targetDay": 225,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 20,
        "targetWeek": 32,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_13",
        "visitName": "Week 35",
        "targetDay": 239,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 27,
        "targetWeek": 35,
        "epoch": "Study Period II: Treatment Period",
        "sourceText": "patient gets assigned, they may be required to come to site for PK-specific visits. Draw PK at ET visit only if patient discontinues study prior to Week 35. Visits 10 and 14 are for all patients, but "
      },
      {
        "id": "visit_llm_22",
        "visitName": "Week 36",
        "targetDay": 253,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 22,
        "targetWeek": 36,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_llm_23",
        "visitName": "Week 42",
        "targetDay": 295,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 23,
        "targetWeek": 42,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_5",
        "visitName": "Week 52",
        "targetDay": 358,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 30,
        "targetWeek": 52,
        "epoch": "Study Period II: Treatment Period",
        "sourceText": "same treatment arm who had their efficacy measure at the Week 52 visit assessed after early discontinuation of study drug and/or initiation of rescue medication (retrieved dropouts). Analysis will be "
      },
      {
        "id": "visit_3",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 31,
        "sourceText": "safety follow-up period, with respect to the following outcomes "
      },
      {
        "id": "visit_llm_25",
        "visitName": "Week 62",
        "targetDay": 435,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 25,
        "targetWeek": 62,
        "epoch": "Study Period III: Treatment Period"
      },
      {
        "id": "visit_llm_26",
        "visitName": "Week 72",
        "targetDay": 505,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 26,
        "targetWeek": 72,
        "epoch": "Study Period III: Treatment Period"
      },
      {
        "id": "visit_llm_27",
        "visitName": "Week 78",
        "targetDay": 547,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 27,
        "targetWeek": 78,
        "epoch": "Study Period III: Treatment Period"
      },
      {
        "id": "visit_llm_28",
        "visitName": "Week 88",
        "targetDay": 617,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 28,
        "targetWeek": 88,
        "epoch": "Study Period III: Treatment Period"
      },
      {
        "id": "visit_llm_29",
        "visitName": "Week 104",
        "targetDay": 729,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 29,
        "targetWeek": 104,
        "epoch": "Study Period III: Treatment Period"
      },
      {
        "id": "visit_llm_801",
        "visitName": "Safety Follow-Up",
        "targetDay": 757,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 801,
        "targetWeek": 108,
        "epoch": "Study Period IV: Safety F/U"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1:1:3",
      "method": "Stratified randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_1",
          "name": "Country",
          "categories": [
            "Category 1",
            "Category 2"
          ],
          "isBlocking": false,
          "sourceText": "country, baseline hba1c concentration (≤8"
        },
        {
          "id": "strat_2",
          "name": "Baseline",
          "categories": [
            "Category 1",
            "Category 2"
          ],
          "isBlocking": false,
          "sourceText": "country, baseline hba1c concentration (≤8"
        },
        {
          "id": "strat_llm_2",
          "name": "Baseline HbA1c concentration",
          "categories": [
            "≤8.5% (≤69 mmol/mol)",
            "˃8.5% (˃69 mmol/mol)"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_3",
          "name": "Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) use",
          "categories": [
            "Yes",
            "No"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "I8F-MC-GPGM(b) Clinical Protocol\nPage 11\nLY3298176\nSummary of Study Design:  \nStudy GPGM is a Phase 3, open-label comparator, multicenter, parallel-arm, randomized study to compare the \nsafety and eff"
    },
    "analysisWindows": [
      {
        "id": "window_treatment_1",
        "windowType": "treatment",
        "name": "Treatment Period",
        "startDay": 3,
        "endDay": 2,
        "description": "Active treatment from Day 3 to Day 2",
        "sourceText": "Treatment\n-3\n-2"
      }
    ]
  }
}